The study results showed significant improvements in motor and quality of life scores, indicating strong efficacy of the AAV-GAD treatment. The absence of serious adverse events enhances the safety profile, making it a promising candidate for further development and regulatory approval. This positive news is likely to boost investor confidence and potentially increase the stock price in the short term.